Sai Parenteral IPO – Global expansion powered by manufacturing and IP

This IPO News guide/article covers “Sai Parenteral IPO – Global expansion powered by manufacturing and IP”. The page is organized around about sai parenteral ipo – opening on march 24, zerodha trade@20, compare stock brokers side-by-side. IPO News presents the structured facts and tables in its own layout and wording.

Topics Covered

• About Sai Parenteral IPO – Opening on March 24
• Zerodha Trade@20
• Compare Stock Brokers Side-by-Side

Key Facts

• India's trusted financial research platform since 2015. Live IPO GMP, subscription data, allotment status, Rights Issues, NCDs and unbiased stock broker reviews.
• 5 manufacturing facilities across India with global regulatory approvals
• Australia facility under development with capex of ₹ 311 crore; Commercialisation in Q4 CY26
• ₹111 crore capex towards EU-GMP upgrades and expansion
• 500+ product dossiers with pipeline expansion
• IPO size of ₹408.79 crore including ₹285 crore fresh issue and ₹123.79 crore in OFS
• Fig.1 – Sai Parenteral Managing Director
• SAI Parenteral’s IPO of ₹409 crore, comprising fresh issue of ₹285 crore and an offer for sale (OFS) of ₹123.79 crore opens from March 24 to March 27.
• The price band fixed is at ₹372-₹392 per share. Given the lot size of 38 shares, the minimum investment fo retail investors is ₹14,896 while non-institutional investors can bid for a minimum of ₹2,08,544.
• Want to start your investment journey? Join India's Pioneer Discount Broker – ZERODHA – Free Delivery Trade, Maximum Rs 20 for F&O and Intraday, Free Direct Mutual Fund investment.
• Why NSE IPO Is One Of India's Most Awaited Listings
• DilMil Partners with Open Atlas Summit 2025 for Immigrant Dating Lounge
• ETT Limited Wins ₹60 Cr Deal, Experts Eye Multibagger Potential at ₹14

Source record: View original public source ↗